Document Detail


Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
MedLine Citation:
PMID:  22258816     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: We previously introduced a classification system for patients with localized pancreatic adenocarcinoma that integrates assessments of tumor anatomy, cancer biology, and patient physiology. By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy.
METHODS: We evaluated consecutive patients (2002-2007) with anatomically potentially resectable cancers treated with chemotherapy or chemoradiation before potential pancreatectomy. We compared clinical factors and outcomes of patients classified as having disease that was clinically resectable (CR; no extrapancreatic disease, preserved performance status); suspicion for extrapancreatic disease (BR-B); or marginal performance status or significant comorbidity (BR-C). Patients with borderline resectable anatomy (BR-A) were excluded.
RESULTS: Resection rates for 138 CR, 41 BR-B, and 38 BR-C patients were 75, 46, and 37%, respectively (P < 0.001). Metastases, detected during treatment in 23% of patients, were the most common contraindication to resection among CR (15%) and BR-B (46%) patients. Performance status rarely precluded surgery except among BR-C (32%) patients. Factors associated with selection against surgery were older age, poor performance status, pain, and therapeutic complications (P < 0.05). The median overall survival of all patients was 21 months. Resected and unresected BR-B and BR-C patients had median overall survival durations similar to those of resected and unresected CR patients, respectively (P > 0.22).
CONCLUSIONS: This system describes discrete clinical subgroups of patients with pancreatic cancer who have similar, potentially resectable tumor anatomy but heterogeneous physiology and cancer biology. It may be used with neoadjuvant therapy to predict outcomes, individualize treatment algorithms, and optimize survival.
Authors:
Ching-Wei D Tzeng; Jason B Fleming; Jeffrey E Lee; Lianchun Xiao; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Robert A Wolff; Gauri R Varadhachary; David R Fogelman; Christopher H Crane; Aparna Balachandran; Matthew H G Katz
Related Documents :
21760506 - Prevention of central nervous system relapses in diffuse large b-cell lymphoma: which p...
19891026 - A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensi...
21645976 - Continued benefit to androgen deprivation therapy for prostate cancer patients treated ...
21659356 - Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoiet...
22210536 - Medical care costs and survival associated with hepatocellular carcinoma among the elde...
2793376 - A phase ii study of spirogermanium in patients with advanced malignant lymphoma.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-01-19
Journal Detail:
Title:  Annals of surgical oncology     Volume:  19     ISSN:  1534-4681     ISO Abbreviation:  Ann. Surg. Oncol.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-21     Completed Date:  2012-10-09     Revised Date:  2014-04-21    
Medline Journal Info:
Nlm Unique ID:  9420840     Medline TA:  Ann Surg Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2045-53     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / mortality,  pathology,  therapy
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carcinoma, Pancreatic Ductal / mortality,  pathology,  therapy
Cisplatin / administration & dosage
Combined Modality Therapy
Deoxycytidine / administration & dosage,  analogs & derivatives
Female
Follow-Up Studies
Humans
Male
Neoadjuvant Therapy / mortality*
Neoplasm Staging
Pancreatectomy / mortality*
Pancreatic Neoplasms / mortality*,  pathology*,  therapy
Prognosis
Retrospective Studies
Survival Rate
Grant Support
ID/Acronym/Agency:
P30 CA016672/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0W860991D6/Deoxycytidine; B76N6SBZ8R/gemcitabine; Q20Q21Q62J/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Novel Genetically Modified Oncolytic Vaccinia Virus in Experimental Models is Effective Against a ...
Next Document:  Safety and efficacy of carboxymethylcellulose in the treatment of glottic insufficiency.